Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Alpine Texworld IPO Review

Alpine Texworld IPO

Alpine Texworld IPO Review

  • The company is an integrated textile manufacturer providing many products under one roof.
  • The company posted growth in its top and bottom lines for the reported periods.
  • It marked improved top and bottom lines on consolidated basis.
  • Outperforming margins for FY26 against shown peers raise eyebrows as it is operating in a highly competitive and fragmented segment.
  • Based on its recent financial data, the issue appears aggressively priced.
  • There is no harm in skipping this pricey and dicey IPO.
Dilip Davda


About Company

Alpine Texworld Ltd. (ATL)erstwhile known as Alpine Spinweave Ltd., is incorporated in February 2016 and began production in April 2017 with the commencement of its weaving unit including the sizing plant at Block No. 614-1105, Village-Paldi, Pirana Miroli Road, Paldi Kankaj, Ahmedabad, Dascroi, Gujarat, India, 382425 (ā€œManufacturing Unit 1ā€). At the time of commencement, the Company installed 48 high-speed Toyota Shuttle less airjet looms in April 2017. Subsequently, in August 2018, the Company further enhanced its production capacity by installing an additional 64 high-speed Toyota Shuttle less airjet looms, bringing increased operational efficiency and scale.

Thereafter, in March 2025, the Company expanded its manufacturing unit by commencing its spinning unit by installation of four (4) open end rotor spinning machines, at Block no 1105, Old Block no 614 (Old Survey no 306), Mouje Paldi Kankaj. Taluka Dascroi, Dist Ahmedabad, Ahmedabad - 11 (Aslali) ā€œManufacturing Unit 2ā€). The Manufacturing Unit 2 is obtained on a leasehold basis from one of its Group Companies/Promoter Group, Alpine Weaving Private Limited and the same is situated adjacent to Manufacturing Unit 1. The decision to establish the spinning plant at Manufacturing Unit 2 ensures operational synergies and management efficiencies with its existing Manufacturing Unit 1. The Manufacturing Unit 1 and Manufacturing Unit 2 collectively includes main building sheds, effluent treatment plants, boiler foundations, machineries, office spaces, raw material storage areas, electrical rooms, water tanks, coal yards, and other auxiliary structures.

The Company has grown into a vertically integrated textile manufacturer with capabilities in weaving and spinning. It procures processed cotton, which is subject to open-end spinning, resulting in yarns (ā€œYarnā€) of varying thicknesses. The Yarns are then woven into grey fabric (ā€œGrey Fabricā€) using looms. 

ATL had installed a rooftop solar plant at (i) Manufacturing Unit 1 with a capacity of 820 KW of solar energy in January 2024 (ā€œSolar Unit 1ā€), and (ii) Manufacturing Unit 2 with a capacity of 475 KW of solar energy in November 2025 (ā€œSolar Unit 3ā€). 

In addition to the rooftop solar panels, the Company has installed ground mounted solar panels at Survey No., 216 (Old Survey No. - 51/2), Khata No. 190, Village - Makhanu, Taluka - Deodar, District – Banaskantha and Survey No., 221 (Old Survey No. - 51/1), Khata No. 190, Village - Makhanu, Taluka - Deodar, District – Banaskantha (ā€œSolar Unit 2ā€) in March 2025 with a capacity of 5.4 megawatts and in April 2026 with an additional capacity of 3.6 megawatts of solar energy, which has further reduced dependency on grid power and promoted cost efficiency. The generated electricity offsets Company’s power consumption, with Uttar Gujarat Vij Company Limited adjusting the same against energy bills. Its top 10 customers contribute around 70% of its total revenue. As of March 31, 2026, it had 164 employees on its payroll.

Alpine Texworld IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 12024000 equity shares of Rs. 10 each to mobilize Rs. 126.25 cr. at the upper cap. The company has announced a price band of Rs. 100 – Rs. 105 per equity shares of Rs. 10 each. The issue opens for subscription on July 14, 2026, and will close on July 16, 2026. The minimum application to be made is for 142 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE and NSE. The issue constitutes 31.44% of the post-IPO paid-up equity capital. From the net proceeds of the issue, the company will utilize Rs. 30.71 cr. for capex on setting up of new weaving unit, Rs. 52.20 cr. for repayment/prepayment of certain borrowing, and the rest for general corporate purposes.

The company has allocated not more than 1% for QIBs, not less than 29% for HNIs and not less than 70% for Retail investors.

The sole Book Running Lead Manager (BRLM) to this issue is D and A Financial Services Pvt. Ltd., and KFin Technologies Ltd. is the registrar to the issue. Giriraj Stock Broking Pvt. Ltd. is a syndicate member.

The company has issued initial equity shares at par value, and has issued further equity shares in the price range of Rs. 76.00 – Rs. 44.66 per share (based on FV of Rs. 10) between March 2017 and December 2020. It has also issued bonus shares in the ratio of 7 for 1 in December 2020. The average cost of acquisition of shares by the promoters is Rs. 1.99, Rs. 2.52, and Rs. 8.01, per share.

Post-IPO, its current paid-up equity capital of Rs. 26.22 cr. will stand enhanced to Rs. 38.25 cr. ased on the upper cap of the price band, the company is looking for a market cap of Rs. 401.59 cr. 

IPO Lead Managers & Registrar

Kfin Technologies Ltd.

Financial Performance

On the financial performance front, for the last three fiscals, the company has posted a total income/net profit, of Rs. 184.44 cr. / Rs. 4.88 cr. (FY24 - Standalone), Rs. 237.66 cr. / Rs. 8.63 cr. (FY25 – Consolidated), and Rs. 350.18 cr. / Rs. 21.72 cr. (FY26 - Consolidated). The company posted growth in its top and bottom lines for the reported periods, but quantum jump in its top and bottom line post consolidated raise eyebrows. Its consolidated contingent liabilities of Rs. 11.94 cr. as of March 31, 2026 raise concern. Its debt equity ratio of 2.35 as of March 31, 2026, raise alarm.

For the last three fiscals, the company has posted an average EPS of Rs. 5.49 and an average RoNW of 22.22 %. The issue is priced at a P/BV of 3.78 based on its NAV of Rs. 27.79 as of March 31, 2026, and at a P/BV of 2.02 based on its post-IPO NAV of Rs. 52.07 per share at the upper price.

If we attribute FY26 earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at P/E of 18.49.  Based on FY25 earnings, the P/E stands at 46.46. The issue appears greedily priced.

For the reported periods, while the company has posted PAT margins of 2.66 % (FY24), 3.63% (FY25), 6.34% (FY26), and RoCE margins of 12.12%, 12.18%, 17.56%, respectively for the referred periods. Outperforming PAT margins for FY26 may not sustain going forward as it is operating in a highly competitive and fragmented segment. 

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2025 ₹237.66 ₹225.82 ₹8.63 ₹294.86
2026 ₹350.18 ₹323.28 ₹21.72 ₹305.31
Alpine Texworld IPO Company Financial Report

Dividend Policy

The company not paid any dividends for the reported periods of the offer document.  It has already adopted a dividend policy in May 2025, based on its financial performance and future prospects.

Comparison with Listed Peers

As per the offer document, the company has shown United Poly, Ken Enterprises, Pashupati Cotspin, as its listed peers. They are currently trading at a P/E of 29.2, 5.54, and 133.0 (as of July 03, 2026). However, they are not truly comparable on an apple-to-apple basis. This comparison appears to be an eyewash. 

Company EPS PE Ratio RoNW % NAV Income
United Polyfab Gujarat Limited 1.07 31.60 18.48% 5.78 682.04 Cr.
Ken Enterprises Limited 6.27 5.27 12.14% 51.68 631.82 Cr.
Pashupati Cotspin Limited 0.66 145.21 6.33% 10.40 687.81 Cr.

Merchant Banker's Track Record

This is the maiden mandate from D and A Financial in the last three fiscals and has no track records in the recent past.

Conclusion

ATL is an integrated textile manufacturer providing many products under one roof. The company posted growth in its top and bottom lines for the reported periods. It marked improved top and bottom lines on consolidated basis. Outperforming margins for FY26 against shown peers raise eyebrows as it is operating in a highly competitive and fragmented segment. Based on its recent financial data, the issue appears aggressively priced. There is no harm in skipping this pricey and dicey IPO.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Alpine Texworld IPO FAQs
1. What is Alpine Texworld IPO? āŒ„
Alpine Texworld IPO is Mainboard IPO. The company is going to raise ₹126.25 Crores via IPO. The issue is priced at ₹100 to ₹105 per equity share. The IPO is to be listed on BSE & NSE.
2. When Alpine Texworld IPO will open for subscription? āŒ„
The IPO is to open on July 14, 2026 for QIB, NII, and Retail Investors. The IPO will close on July 16, 2026.
3. What is Alpine Texworld IPO Investors Portion? āŒ„
The investors’ portion for QIB is 1%, NII is 29%, and Retail is 70%.
4. How to Apply the Alpine Texworld IPO? āŒ„
You can apply for Alpine Texworld IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Alpine Texworld IPO Issue Size? āŒ„
Alpine Texworld IPO issue size is ₹126.25 crores.
6. What is Alpine Texworld IPO Price Band? āŒ„
Alpine Texworld IPO Price Band is ₹100 to ₹105.
7. What is Alpine Texworld IPO Lot Size? āŒ„
The minimum bid is 142 Shares with ₹14,910 amount.
8. What is the Alpine Texworld IPO Allotment Date? āŒ„
Alpine Texworld IPO allotment date is July 17, 2026.
9. What is the Alpine Texworld IPO Listing Date? āŒ„
Alpine Texworld IPO listing date is July 21, 2026. The IPO is to list on BSE & NSE.

Leave a Reply

Your email address will not be published. Required fields are marked *

Picture of Dilip Davda

Dilip Davda

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985. He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.
Picture of Dilip Davda

Dilip Davda

Leave a Reply

Your email address will not be published. Required fields are marked *

Join WhatsApp Channel